“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Developing new chemical entities for focused therapy areas
Producing quality medicines in areas of
Producing high quality affordable
and accessible biologics
December 24, 2019
December 20, 2019
December 19, 2019
December 18, 2019
December 03, 2019
November 22, 2019
November 19, 2019
November 11, 2019
November 08, 2019
November 07, 2019
November 06, 2019
November 01, 2019
October 23, 2019
October 22, 2019
October 18, 2019
October 09, 2019
October 04, 2019
October 03, 2019
October 01, 2019
September 30, 2019
September 25, 2019
September 20, 2019
September 13, 2019
September 09, 2019
September 06, 2019
September 04, 2019
August 26, 2019
August 22, 2019
August 16, 2019
August 08, 2019
August 07, 2019
August 06, 2019
August 05, 2019
July 22, 2019
July 09, 2019
July 03, 2019
June 27, 2019
June 04, 2019
May 30, 2019
May 29, 2019
May 22, 2019
May 15, 2019
May 14, 2019
May 10, 2019
May 09, 2019
May 07, 2019
April 30, 2019
April 16, 2019
April 12, 2019
April 11, 2019
April 10, 2019
April 03, 2019
April 02, 2019
April 01, 2019
March 28, 2019
March 27, 2019
March 26, 2019
March 25, 2019
March 22, 2019
March 07, 2019
March 05, 2019
February 28, 2019
February 26, 2019
February 25, 2019
February 15, 2019
February 12, 2019
February 11, 2019
February 07, 2019
February 06, 2019
February 05, 2019
February 01, 2019
January 28, 2019
January 21, 2019
January 18, 2019
January 08, 2019
January 07, 2019
The world is grappling with an unprecedented crisis. The focus remains not only on controlling the spread of Covid-19, but on ensuring the safety of those who are working at the frontlines of the pandemic to contain it and those whose livelihoods have been severely impacted by it.
At Lupin, we are moving ahead with a clear strategy of safety and preparedness. At the onset of the crisis, we set up a centralized ‘Covid-19 Taskforce’ to monitor the situation daily and put in place adequate safeguards to ensure the health and safety of our employees, develop a business continuity plan, and support the communities we operate in.
All our factories have been maximizing the production of life-saving drugs to ensure that despite the ongoing crisis, our drugs remain available for our communities around the world. We have ramped up production of hydroxychloroquine sulphate and Azithromycin – two drugs being explored as potential treatment for Covid-19.
While our manufacturing site employees are committed towards meeting your healthcare needs, we are committed to their health and safety. We have ensured: complete sanitization of our premises, as well as that of the company buses and cabs that our employees use; thermal screening for employees working at sites; providing sanitizers and masks to employees and support staff at all our premises. Additionally, we are also following all protocols and guidelines issued by global health organizations for COVID-19 to keep our employees safe.
Our Supply Chain team is taking all appropriate actions to ensure that any disruption is minimal and we continue to function regularly during this uncertain time.
Our team at Lupin Human Welfare and Research Foundation is dedicating efforts towards production of face masks for personnel involved in essential services; packed meals are also being served in Madhya Pradesh and Rajasthan to migrant workers who have been worst hit in this crisis.
The fact remains that this is a complex situation where despite our best efforts, we all face an uncertain tomorrow. You have our promise that we remain committed to providing you with access to quality healthcare at an affordable price.
Mrs. Manju D. Gupta is one of the promoters of the Company. She has intimate knowledge of the Company right since inception. Mrs. Gupta has been a Member of the Board for over four decades and has been an important pillar of strength for the Company. She has wide business experience and expertise and has been on various Committees of the Board and also involved in the CSR activities of the Company. Mrs. Gupta has made significant contribution in building the Company as one of the top corporates in India.
Mrs. Manju D. Gupta was Executive Director of the Company till August 10, 2017. The Board of Directors elevated her as Non-Executive Chairperson of the Company effective August 11, 2017.
Goa plant foundation stone Project startup was done in August 2003 and it was built up in record time of only 6 months to start operations in Feb 2004 Pilot scale operations started in March / April 2004 with initiation of Exhibit batches of Lisinopril tablets for US market and EU market. The plant started with a Manpower total strength of only 30 people in 2004. First US & EU Regulatory filing for Lisinopril tablets from Goa was done which made Goa sail through its first USFDA Pre Approval inspection in June 2005 and MHRA inspection in Nov 2005.
Goa plant has been subjected to multiple extensions & plant-02 operational in 2015.Goa plant manufacture and deliver oral dosage forms with a capacity of more than 9 Billion units / Annum. Till date Goa plant has executed more than 350 Exhibit Products for US, EU, AU, Japan &Brazil markets. It has been inspected by USFDA six times and MHRA five. It is also inspected by WHO Indian agency four times & by ANVISA once. Commercial supplies to US & EU market were initiated with product Lisinopril tablets in Nov 2005 & Aug 2007 respectively. As on date the plant supplies more than 100 Products to regulated markets of US, EU & AU. Goa plant has filed as on date more than 115 ANDA’s in US market, more than 80 filings in EU & AU market,10 ANDA’s for Japan market and 03 ANDA’s for Brazil Market.
Goa plant major production volume supply to US Market with Quality is major objective. High skilled & qualified personnel engaged in manufacturing, packing & quality testing of products in world class facility.
Goa plant having Project Disha-A manufacturing excellence initiative – build a sustainable operating model for improving and sustaining profitability by developing continuous improvement capabilities within Lupin.
Year of foundation: 2003
Address: B-15, Phase 1A, Verna Industrial Area, Verna Salcette-Goa 403722
No. of Plants: 02
Nature of business: Formulations – Solid Oral Facility
Size of the facility: 34710.59 sqm
Approvals: US FDA / MHRA / WHO/ANVISA/PMDA-Japan/TGA
Pithampur site is one of the Lupin’s largest formulations facility located at Indore Special Economic Zone (ISEZ) and is about 30 Km from Indore city. Hindi is the common language spoken in the area and Indore is well connected by Air, Train and Road. This is the only site of Lupin having capability to manufacture various finished dosage forms like Tablets, Capsules, Ophthalmics, Dermatological Preparations, Metered Dose Inhalers (MDI), Dry Powder Inhalers (DPI) as well as Active Pharmaceutical Ingredients (API). This Facility has been inspected by US FDA, UK MHRA, Germany BfArM and WHO. This site has got honor to become the first site certified by SA 8000. As on date this site supplies to regulated markets of USA, UK, France, Germany, Australia and Canada.This site has 3 sub units, where :
Unit-1 is having dedicated plants for manufacturing of Oral Formulations and Active Pharmaceutical Ingredients (API) (Manufacturing capacity – 1 Billion Tablet/Capsules and 30 to 140 Kg API).
Unit-2 is having dedicated plants for manufacturing of Oral Formulations and Sterile Ophthalmics (Manufacturing capacity – 10 Billion Tablet/Capsules and 6 Million Ophthalmics).
Unit-3 is having dedicated modules for Manufacturing of Dermatological, Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Formulations (Manufacturing capacity – Derm-6 Million units, MDI-3 Million units, DPI – 178 Million units).
Year of foundation:
Plot No.2 – Unit 1&2 – November 2007,
Plot No.M1- Unit 3 – October 2010
Address Unit 1&2:
Plot No. 2, Special Economic Zone Phase – II, Miscellaneous Zone, Apparel Park, Pithampur, Dist.- Dhar, MP- 454 775, INDIA
Address Unit 3:
Plot No. M1, Special Economic Zone Phase – II, Miscellaneous Zone, Apparel Park, Pithampur, Dist.- Dhar, MP- 454 775, INDIA
No. of Plants: 7 (4 Formulation + 3 API)
Nature of business: Manufacturing of Formulations and Active Pharmaceutical Ingredients (APIs)
Size of the facility :
Plot No.2 (Unit 1&2): 107965 sqm
Plot No.M1 (Unit 3): 50039 sqm
Total Employees: 1345
Approvals: US FDA / UK MHRA / Germany BfArM / WHO / SA 8000
This site has state of art in manufacturing wide range of products in various categories like CRAMS, Pharmaceuticals Intermediates and APIs for international as well as domestic sale. It has well equipped and multi range facilities to deliver the products in the range of developmental quantity to commercial scale. Facilities are well designed and qualified to meet the cGMP requirement and having a competent workforce for the need. It is also backed up with onsite R&D center. Site is emerging as one of the facility for manufacturing APIs for advance markets.
Year of foundation: 2007 (Acquired from Rubamin Pharmaceuticals).
Address: Block 21, Village Dabhasa, Ta-Padra Vadodara 391440
No. of Plants: 6
Nature of business: Intermediates and API Manufacturing
Size of the facility: 30 acres
Approvals: ISO-9001 / ISO-14001 / OHSAS-18001 / WHO cGMP
Lupin’s latest formulation facility is located in Special Economic Zone, SEZ, Nagpur, MS, Central part of India. Dedicated facility for manufacturing of solid oral dosage forms.
Manufacturing capacity: Existing block is designed for exhibit batches for USA, EU, WHO & ROW Market
Address: Plot 6A, Sector 17, SEZ, MIHAN Notified area, Nagpur, Maharashtra, India 441108
No of plants: 01 EB
Plant inception: Aug 2013
Nature of business: Manufacturing of formulations
Size of the facility: 60703 Sq M
Approvals: Approved by WHO, USFDA
Plant Operations started in: 2015
Year of Foundation: 2015
Address: 4th Mile, Bhasmey, Karmarey-Bhasmey Block, Duga Iilaka, East Sikkim, Sikkim- 737132 India.
No.of Plants: One Block
Nature of business: Manufacturing – Formulation
Size of the facility: Total Area 28779.92 sq. meter & Built up Area – 11513 sq. meter
No.of employees: 180
Approvals: Local FDA ( Manufacturing & Sales)
Address: Plot No.130, Road No.11, J.N.Pharma City, Parawada (M), Visakhapatnam, Andhra Pradesh , India – 531019
No.of Plants: 2 Blocks comprising 4 independent manufacturing streams.
Nature of business: API Manufacturing
Size of the facility: 27.71 Ac
No.of employees: 150
Approvals: Drug Control Authority, Govt.of A.P
The Plant is located at about 17 Kms. from Jammu city. Jammu is also known as “City of Temples” and Winter Capital of J&K. The Temperature in winter goes to Min- 1-3 Deg C and 46-47 Deg C during Summers. Dogri, Hindi, Punjabi, Kashmiri, Urdu are the common languages spoken in the area. Jammu is well connected by train, road and air. Delhi is 600 Kms. and Srinagar (Summer Capital of J&K) 300 Kms. from Jammu.
Year of foundation: March 2006
Plant Address: EPIP Kartholi, SIDCO Industrial complex, Bari Brahmana Dist. Samba, Jammu & Kashmir 181133
No. of Plants: 1
Nature of business: Formulations
Size of the facility: 59 Kanals (7.36 acres)
Approvals: WHO Geneva ,Ukraine MOH, CDSCO (INDIA) approval as per WHO guidelines.
The manufacturing facility for APIs has been started in 1992 and has a state-of-art fermentation facility and synthetic API manufacturing Multi product plants. The Facility has been inspected by US FDA, MHRA,WHO, KFDA & COFEPRIS. It has a captive power plant (with 100% back up).
Year of Foundation: 1992
Address: T-142, MIDC, Tarapur, Boisar (West), Dist. Thane, Maharashtra 401506
No. of Plants: 16 Manufacturing Plants and 5 Solvent Recovery blocks
Nature of business: Manufacturing of “Active Pharma Ingredient” (Fermentation based and synthetic)
Size of the facility: 2,18,171 Sqm (built-up area is 92,055 sqm.)
Approvals: US FDA / MHRA / WHO / KFDA / COFEPRIS
This facility is engaged in the manufacturing of APIs as well as dosage forms which produces Sterile and Non-Sterile pharmaceutical products and mainly caters to the US and Europe markets.
Year of foundation: 1986
Address:198-202, New Industrial Area No. 2, Mandideep, Dist. Raisen 462046, M.P
No. of Plants: 9
Nature of business: Manufacturing of APIs (Cephalosporins & Cardiovascular) and Formulations
Size of the facility: 58 acres
Approvals: US FDA / UK MHRA / AFSSAPS-France / TGA-Australia / WHO
Aurangabad Plant operation started in 1979. This is the first plant of Lupin with various dosage forms like Tablets, Capsules and Liquids.
Year of foundation: 1979
Address: A/28/1, MIDC Industrial Area, Chikalthana, Aurangabad – 431 210
Nature of business: Manufacturing of tablets, capsules and liquids
Size of the facility: 60000 sqm
Employees: 362 (As on 17th February, 2016)
Approvals: WHO / US FDA / MCC / TGA / ANVISA / German
The Company is an ISO 14001:2004 and OSHAS 18001:2007 Company. It has well integrated environment system to treat the effluent water whereby the characteristics are below the norms of Gujarat Pollution Control Board. Manufacturing practices are in compliance to cGMP norms.Year of foundation: 1982
Address: Lupin Limited,
Plot No. 09,123,123/1,124 & 125, GIDC Estate, Ankleshwar 393002 (Gujarat)
No. of Plants: 11
Nature of business: Manufacturing Intermediates and Bulk drugs
Size of the facility: 40 acres
Approvals: FDA / CCA/ WHO GMP / KFDA / ISO 14001:2004 / OSHAS 18001:2007 / MHRA / WHO Geneva / ANVISA / EDQM / ISRS
Vinita Gupta is the CEO of Lupin Limited (Lupin) and Chairperson of Lupin Inc., (LI) and its US subsidiary, Lupin Pharmaceutical Inc. (LPI).
Vinita is a graduate in pharmacy from the University of Mumbai and earned an MBA degree at the Kellogg School of Management at Northwestern University. Vinita has been instrumental in formulating and executing a strategy that has helped the company emerge as a global pharmaceutical powerhouse; amongst the most exciting growth stories in the pharmaceutical industry. Through a combination of organic growth and strategic acquisitions, she has led the company’s global expansion plans. In particular, she founded, led and established Lupin’s largest region, the United States.
Vinita has been regularly named by Forbes Asia in its Top 50 Power Business women listings for Asia Pacific. Vinita was also recognized by Business Today Hall of Fame – Most Powerful Women in Business in 2016 and was recently named Outstanding Business Woman Leader of the Year by CNBC India Business Leader Awards. She was the winner of the inaugural EY, U.S. 2012 Family Business Award of Excellence and EY Entrepreneur Of the Year® 2012 award winner for Health Services and Technology in Maryland. She is regarded as amongst the most influential Indian Business Women globally.
Vinita along with her brother Nilesh (Managing Director, Lupin Limited) were named Ernst & Young (EY) Entrepreneur of The Year 2015 and won the Forbes India Leadership Awards 2016, Entrepreneur of the Year.
In 2017 Vinita was appointed to the board of directors for Intrexon Corporation. She is also a member of the Global Advisory Board at the Kellogg School of Management at Northwestern University.
Mr Belingard, a French national, graduated from Ecole des Hautes Etudes Commerciales (HEC), France and completed Master of Business Administration from Cornell University, USA. Mr Belingard started his career with Merck, Sharp and Dohme. He moved to F. Hoffman-La Roche, Basel, Switzerland. He was Member of the Executive Committee, F. Hoffman-La Roche Ltd. and Chief Executive Officer, Roche Diagnostics, Basel, Switzerland. He was Chief Executive Officer, bioMerieux-Pierre Fabre, France. He was Chairman and Chief Executive Officer, Ipsen Group, France. In 2011, he joined bioMerieux S.A. as Chief Executive Officer and became its Chairman in April 2014. Mr Belingard is a Member of the Board of Directors of Laboratory Corporation of America, (U.S.A.), Stallergenes (France/U.S.A.), Transgene (France) and Laboratoire Pierre Fabre, (France). He is also a Member of the Bill and Melinda Gates Foundation. Mr Belingard is also Foreign Trade Advisor to the French Government. Mr Belingard has been conferred upon the prestigious National Awards, Chevalier de I’Ordre National du Merite and Chevalier de la Legion d’Honneur awards.
File size : 2.2 MB
Mr Dileep C Choksi, a leading Chartered Accountant by profession, has over 35 years of experience having qualified as a lawyer and a Cost Accountant. His areas of specialisation include tax planning and structuring for domestic and international clients, including expatriates, finalising collaborations and joint ventures, executive advisory and decision support, corporate restructuring with a focus on startup, turnaround and change management strategies and analysing tax impact of various instruments. He advises some of India’s largest business houses on various strategic matters and multinational clients on cross border structuring. Mr Choksi is on the Board and Committees of leading corporates. He was on the Advisory Board of foreign banks as well as Ex-Chairman of Banque Nationale De Paris, Bombay. He was the former Vice Chairman of Deloitte in India before setting up of C3 Advisors. The activities at C3 aim to provide complete answers for all business needs.
A Ph.D.in Economics from University of Bombay, with a Certificate in Financial Management from JBIMS, Dr K U Mada is an eminent economist and development banker. He has served in key positions with IDBI as its Executive Director for over three years. He was Chairman/Member of a number of committees constituted by IDBI and other financial institutions and the Government of India.
With more than 30 years of experience in the Biotechnology and Pharmaceutical Industries globally, Mr Richard Zahn is a well recognized thought leader and strategist in healthcare research and development, professional and consumer marketing, corporate strategy, sales force management, managed care, State and Federal relations, and human resources. Prior to this, Mr Zahn was the President of Schering Laboratories, Director, Schering Corporation and Corporate Vice President of Schering-Plough Corporation. As President of Schering, he directed the Corporation’s primary business unit through the most dynamic growth period in its history, transforming it from a US $1.5 billion organization to a US $ 6 billion major company. Under his stewardship, Schering Laboratories created and developed important prescription therapeutic markets. His leadership transformed Schering-Plough Healthcare Products (OTC company for Schering-Plough) into a major force. Mr Zahn spent 20 years rising through the ranks with increasing responsibility at Johnson & Johnson before being recruited to the Senior Management levels at Schering-Plough.
Mr R A Shah is an eminent Solicitor specialising in a broad spectrum of Corporate Laws. He is a senior partner of Crawford Bayley & Company, a leading firm of Solicitors and Advocates in Mumbai. He is on the boards of several reputed companies. Mr Shah is a member of the Managing Committee of Bombay Chamber of Commerce and Indo German Chamber of Commerce. He is President of Society of Indian Law Firms (Western Region).
Ms. Mundkur most recently served as Chief Executive Officer and Non-voting Chairman of the Board of Directors for Impopharma Inc, a developer of complex formulations focused on inhalation pharmaceutical products. While at Impopharma, she led the transition of the company from a successful clinical research organization into a generic pharmaceutical inhalation development company. She also held leadership positions as President and Chief Executive Officer for North America for Sandoz, Inc. Earlier, she served as Chief Executive Officer of Barr Laboratories, Inc. Ms. Mundkur started her career at Barr as quality and regulatory counsel. In addition, she served as a strategic advisor to clients on generics, 505(b)2, biosimilars and NDA business strategies. She currently serves on the Board of Directors for MannKind Corporation in the U.S.
Ms. Mundkur holds a J.D. from the St. Louis University School of Law and also received a B.S. degree in chemistry from St. Louis University.
File size : 1.8 MB
Mr. Nilesh Gupta is the MD of Lupin Limited and a member of the Board of Directors. Having joined Lupin in 1996, Mr. Gupta led Lupin’s research, supply chain, manufacturing, quality and regulatory operations, and took charge as the company’s Managing Director in 2013. He has not only been responsible for transforming Lupin’s research program and expanding the company’s manufacturing operations but has also been instrumental in formulating and executing the core strategy that has helped Lupin emerge as a global specialty pharmaceutical major.
Mr. Gupta, along with his sister Vinita Gupta, won the Entrepreneur of the Year award at Forbes India Leadership Awards in 2016 as well as Ernst & Young ‘Entrepreneur of the Year Award’ in India in 2015, also with his sister Vinita Gupta.
Mr. Gupta is a Chemical Engineer from the University Department of Chemical Technology (UDCT) (now ICT), Mumbai, and a graduate with honours from the Wharton School, University of Pennsylvania, USA, where he specialized in healthcare, strategic management and finance.
Dr. Kamal K. Sharma is the Vice Chairman of the Board of Lupin Limited, in a Non-Executive capacity. In a career spanning more than four decades, Dr. Sharma has held a range of senior management positions managing projects, operations, corporate development and general management in the pharmaceuticals and chemicals industries. He was the Managing Director of Lupin Chemicals Limited which was rechristened Lupin Limited upon amalgamation with Lupin Laboratories Limited. Thereafter, he joined RPG Life Sciences, as President and Chief Executive Officer. In 2003 he rejoined Lupin Limited as Managing Director, following which he was appointed as Vice Chairman in 2013.
Dr. Sharma is a chemical engineer from Indian Institute of Technology (IIT), Kanpur, with a post-graduate diploma in industrial management from Jamnalal Bajaj Institute of Management Studies, Mumbai, and a Ph.D. in economics from IIT, Mumbai. He has also completed an advanced management programme from Harvard Business School, Boston.